Geneva, Nov. 2 -- International Clinical Trials Registry received information related to the study (ChiCTR2600134709) titled 'A Comparative Study of Letermovir and Valganciclovir for the Prevention of Cytomegalovirus Infection in Adult Lung Transplant Recipients' on Oct. 20.
Study Type: Interventional study
Study Design:
Parallel
Primary Sponsor: The second affiliated hospital of Zhejiang University school of medicine
Condition:
Rejection and infection after adult lung transplantation
Intervention:
Letermovir group:Letemovir 480mg, orally, once a day. If used in combination with cyclosporine, the recommended dose of letemovir is 240mg once daily.
Recruitment Status: Not Recruiting
Phase: 3
Date of First Enrollment: 2026-11-01...